

# AtriCure Prices Public Offering of Common Stock

The Associated Press

WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan 16, 2013--AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced the pricing of its previously announced underwritten public offering of 3,475,000 shares of its common stock at a public offering price of \$7.25 per share. In connection with the offering, AtriCure has also granted the underwriter a 30-day option to purchase up to an additional 521,250 shares of common stock to cover over-allotments, if any. Piper Jaffray & Co. is acting as the sole manager for the offering.

Net proceeds from the sale of the shares after underwriting discounts and commissions and other offering expenses are expected to be approximately \$23.5 million. The offering is subject to customary closing conditions and is expected to close on Tuesday, January 22, 2013.

AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital.

The offering was made pursuant to a prospectus supplement to AtriCure's prospectus, dated July 20, 2011, filed as part of AtriCure's effective \$50 million shelf registration statement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Copies of the preliminary prospectus supplement and accompanying prospectus relating to these securities may be obtained by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at [prospectus@pjc.com](mailto:prospectus@pjc.com).

About AtriCure, Inc. AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage. The Company believes cardiothoracic surgeons are adopting its ablation products for the treatment of AF during concomitant open-heart surgical procedures and sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke. The FDA has not cleared or approved certain AtriCure products for the treatment of AF or a reduction in the risk of stroke.

## **AtriCure Prices Public Offering of Common Stock**

Published on Medical Design Technology (<http://www.mdtmag.com>)

---

Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure’s products. Forward-looking statements are based on AtriCure’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure’s products, AtriCure’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure’s products, competition from existing and new products and procedures or AtriCure’s ability to effectively react to other risks and uncertainties described from time to time in AtriCure’s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: AtriCure, Inc.

Andy Wade, Vice President and Chief Financial Officer, 513-755-4564  
awade@atricure.com or Investor Relations Contact: Westwicke Partners Lynn  
Pieper, 415-202-5678 Lynn.pieper@westwicke.com  
KEYWORD: UNITED STATES  
NORTH AMERICA OHIO INDUSTRY KEYWORD: SENIORS WOMEN SURGERY HEALTH  
CARDIOLOGY HOSPITALS MEDICAL DEVICES RESEARCH FDA CONSUMER SCIENCE  
MEN SOURCE: AtriCure, Inc. Copyright Business Wire 2013 PUB: 01/16/2013 09:00  
AM/DISC: 01/16/2013 09:00 AM  
<http://www.businesswire.com/news/home/20130116005759/>

**Source URL (retrieved on 03/06/2015 - 7:42am):**

[http://www.mdtmag.com/news/2013/01/atricure-prices-public-offering-common-stock?qt-video\\_of\\_the\\_day=0&qt-most\\_popular=0](http://www.mdtmag.com/news/2013/01/atricure-prices-public-offering-common-stock?qt-video_of_the_day=0&qt-most_popular=0)